Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

GeoVax Labs, Inc. - Common Stock (NQ:GOVX)

0.6686 +0.0186 (+2.86%)
Streaming Delayed Price Updated: 2:06 PM EDT, Jul 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about GeoVax Labs, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
GeoVax Labs Announces $4.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
ATLANTA, GA - March 24, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases,... 
Via TheNewswire.com
Topics Regulatory Compliance
GeoVax to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 27, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 27, 2025
GeoVax to Host Conference Call at 4:30 PM ET 
Via TheNewswire.com
GeoVax Pledges Continued Support for Vaccine Innovation, Transparency, and Public Health
GeoVax’s Vaccine Development Programs Align with Anticipated HHS Focus on Vaccine Safety, Diversification and Domestic Biosecurity 
Via TheNewswire.com
GeoVax Labs Inc. (NASDAQ: GOVX) Featured in Coverage of the 37th Annual ROTH Conference
Via Investor Brand Network
GeoVax Establishing Strategic Presence in Europe With Initial Footprint in the UK
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax Establishing Strategic Presence in Europe With Initial Footprint in the UK
Hub to Advance Global Vaccine and Immuno-Oncology Development 
Via TheNewswire.com
GeoVax to Present at the 37th Annual Roth Conference
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax to Present at the 37th Annual Roth Conference
ATLANTA, GA - March 11, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today... 
Via TheNewswire.com
Registration is Now Open For Tribe Public's CEO Presentation and Q&amp;A Webinar Event MPOX 2025: Navigating the Global Public Health Emergency Featuring GeoVax CEO On March 6, 2025
ATLANTA, GA - March 4, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases,... 
Via TheNewswire.com
Registration is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event MPOX 2025: Navigating the Global Public Health Emergency Featuring GeoVax CEO On March 6, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax Highlights the Critical Role of MVA-Based Vaccines in U.S. Biodefense Strategy
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Economy
GeoVax Highlights the Critical Role of MVA-Based Vaccines in U.S. Biodefense Strategy
GeoVax’s GEO-MVA: Strengthening U.S. Biodefense 
Via TheNewswire.com
Topics Economy
GeoVax Response to WHO's Third Declaration of Mpox as a Public Health Emergency of International Concern
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Death
GeoVax Response to WHO's Third Declaration of Mpox as a Public Health Emergency of International Concern
GeoVax Advancing GEO-MVA Vaccine Candidate to Bolster Global Supply Options 
Via TheNewswire.com
Topics Death
GeoVax Highlights the Role of MVA-Based Vaccines in Advancing Public Health Preparedness
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax Highlights the Role of MVA-Based Vaccines in Advancing Public Health Preparedness
Recent Studies Support Diversified Vaccine Strategies, Aligning with GeoVax’s MVA-Based GEO-CM04S1 for Enhanced Protection, Particularly for Immunocompromised Populations 
Via TheNewswire.com
Mpox Clade 1 in the U.S. Highlights the Need for Vaccine Supply Diversification
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Economy Supply Chain
Mpox Clade 1 in the U.S. Highlights the Need for Vaccine Supply Diversification
GeoVax Advances GEO-MVA to Strengthen U.S. and Global Readiness 
Via TheNewswire.com
Topics Economy Supply Chain
GeoVax Pledges Continued Support for Vaccine Innovation, Transparency, and Public Health
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax to Present at the Emerging Growth Conference on February 19, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax to Present at the Emerging Growth Conference on February 19, 2025
Company to Provide an Update on Its Mpox Vaccine Program 
Via TheNewswire.com
GeoVax Congratulates Dr. Valerie Montgomery Rice on Receiving the 2025 Healthcare Champions Lifetime Achievement Award
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax Congratulates Dr. Valerie Montgomery Rice on Receiving the 2025 Healthcare Champions Lifetime Achievement Award
Recognizing a Visionary Leader in Advancing Healthcare Access for Minority and Vulnerable Populations Worldwide 
Via TheNewswire.com
GeoVax Anticipates Significant 2025 Progress With Catalyst-Rich Milestones Across Key Programs
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Artificial Intelligence
GeoVax Anticipates Significant 2025 Progress With Catalyst-Rich Milestones Across Key Programs
Strategic Progress Across COVID-19, Mpox, Oncology Therapies and AI Integration Positions GeoVax for Strong Momentum 
Via TheNewswire.com
Topics Artificial Intelligence
GeoVax to Showcase Advancements in Vaccines & Immunotherapies at the 2025 BIO CEO & Investor Conference
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax to Showcase Advancements in Vaccines &amp; Immunotherapies at the 2025 BIO CEO &amp; Investor Conference
ATLANTA, GA - February 4, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced... 
Via TheNewswire.com
GeoVax Announces Strategic Integration of AI in Support of President Trump's Stargate Initiative
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Artificial Intelligence Government
GeoVax Announces Strategic Integration of AI in Support of President Trump's Stargate Initiative
Harnessing AI to Revolutionize Vaccine and Therapy Development 
Via TheNewswire.com
Topics Artificial Intelligence Government
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.